Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia

Fig. 1

Outline of patient enrollment in this study. AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; TP1, on days 28–35 after the first induction course; TP2, at the end of the second induction course (before start of consolidation); MFC, multiparametric flow cytometry; MRD, minimal residual disease; HSCT, hematopoietic stem cell transplantation; CR1, first complete remission

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us